Mi az ára ZIOPHARM Oncology, Inc. (ZIOP)

ZIOPHARM Oncology, Inc. (ZIOP) ára $0.8657

Mi a ZIOPHARM Oncology, Inc. (ZIOP piaci tőkésítése)

ZIOPHARM Oncology, Inc. piaci tőkésítése (ZIOP) $122.22M

ZIOPHARM Oncology, Inc. (ZIOP) Egy Részvényre Jutó Nyereség

ZIOPHARM Oncology, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing innovative immuno-oncology treatments for cancer patients. The company leverages its proprietary Sleeping Beauty platform, which employs non-viral genetic engineering to modify T-cells outside the body using a transposon/transposase system for subsequent infusion. Additionally, ZIOPHARM is advancing its Controlled IL-12 technology, designed to precisely regulate the expression of interleukin-12 (IL-12), a key immune system regulator, to direct the patient's immune response against cancer cells. Its pipeline features several promising therapeutic candidates, including T-cell receptor (TCR) plus T-cell therapies aimed at solid tumors, chimeric antigen receptor (CAR) T-cell therapies specifically targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 combined with veledimex, a gene delivery system for controlled IL-12 production under investigation for treating recurrent adult glioblastoma multiforme. ZIOPHARM maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., and research and development agreements, alongside patent licensing, with institutions such as The University of Texas MD Anderson Cancer Center and the National Cancer Institute. The company's headquarters are located in Boston, Massachusetts.

Év	EPS	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

EPS

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	EPS	EPS különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Vállalat

EPS

EPS különbség

Ország